Patent · US Active

Use of pemirolast

US9415051B1 · kind B1 · utility

0Cited by

1References

7Claims

0Family size

Assignee

RSPR Pharma AB · SE

Inventors

Johan Raud · Stockholm, SE
Carl-Johan Dalsgaard · Stockholm, SE
Göran Tornling · Enebyberg, SE

Key dates

Filing date	Nov 24, 2015
Grant date	Aug 16, 2016
Priority date	—
Expiry date	Nov 24, 2035

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D487/04
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

According to the invention there is provided a method for the treatment of airway hyperresponsiveness, which method comprises the administration of pemirolast, or a pharmaceutically acceptable salt thereof, to a patient in need of such treatment. Suitable lower doses of pemirolast are least about 110 mg per day.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.